Demonstrated that BPC-157 improves insulin signaling and reduces TNF- and IL-6 release in hepatocyte cultures exposed to high-glucose conditions, providing a new model for studying metabolic-dysfunction pathways
Data extraction and quality assessment were performed, focusing on primary outcomes, including changes in triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), and secondary outcomes including blood pressure (BP) and body mass index (BMI)
One of the biggest frustrations for patients is that GLP-1 side effects can overlap with hypothyroid symptoms
In September 2023, the FDA listed BPC-157 as a Category 2 bulk drug substance
It can be naturally found in chamomile essential oil